Richard Saynor appointed as new Sandoz CEO

GSK’s Richard Saynor is a qualified pharmacist who graduated from Bradford University with a Bachelor of Pharmacy, and is a member of the Royal Pharmaceutical Society. He has now been appointed chief executive officer of Sandoz, GSK’s biosimilars and generics division.
Mr Saynor joined GSK in September 2010 and in his current tenure of Senior Vice President, Classic and Established Products, Commercial & Digital Platforms he is responsible for driving sales, leveraging the supply chain and maximising operating profit for post-patent products in Respiratory, Allergy, Anti-infective, Neuroscience, Dermatology and Urology. He brings more than 20 years’ experience in the generics and pharma industry with him to his new appointment, having held senior leadership positions in Asia, Latin America, Canada and Europe. Prior to joining GSK, Mr Saynor worked at Sandoz and helped manage an expansion of its generics business across Asia, Latin America and Turkey.